NCT07441694 2026-03-19
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
Clinical Trials
26 trialsNCT02386800 2026-03-16
CINC424A2X01B Rollover Protocol
Novartis
Phase 4 Active not recruiting
NCT07469891 2026-03-13
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
Phase 1 Not yet recruiting
NCT06985147 2026-03-04
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Disc Medicine, Inc
Phase 2 Recruiting
NCT07232290 2026-03-04
Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2 Recruiting
NCT06351631 2026-02-20
MK-3543-017
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06093672 2026-01-27
GIV-IN-PV
Italfarmaco
Phase 3 Recruiting
NCT05143957 2026-01-16
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
Ionis Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT06743035 2026-01-09
ROPE
iOMEDICO AG
Recruiting
NCT05499013 2025-12-19
SLN
Silence Therapeutics plc
Phase 1/2 Active not recruiting
NCT04745637 2025-11-18
Managed Access Programs for INC424, Ruxolitinib
Novartis
Available
NCT05269771 2025-11-05
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
Novartis
No longer available
NCT04182100 2025-09-15
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
PharmaEssentia Japan K.K.
Phase 2 Completed
NCT05548062 2025-09-03
Prospero
Novartis
Active not recruiting
NCT04629508 2025-09-02
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Incyte Corporation
Phase 2 Completed
NCT06378437 2025-08-19
A Study of GLB-001 in Patients With Myeloid Malignancies
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05481151 2025-08-13
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
PharmaEssentia
Phase 3 Active not recruiting
NCT04057040 2025-08-07
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
Protagonist Therapeutics, Inc.
Phase 2 Completed
NCT05210790 2025-08-07
VERIFY
Protagonist Therapeutics, Inc.
Phase 3 Active not recruiting
NCT06033586 2025-08-06
THRIVE
Protagonist Therapeutics, Inc.
Phase 3 Active not recruiting
NCT05485948 2025-08-03
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
PharmaEssentia
Phase 2 Active not recruiting
NCT06290765 2025-07-31
PV
PharmaEssentia
Phase 4 Not yet recruiting
NCT05558696 2025-07-29
MK-3543-004
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Phase 2 Completed
NCT07012109 2025-06-10
Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)
BeBetter Med Inc
Phase 1 Not yet recruiting
NCT06752746 2025-05-11
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1 Recruiting
NCT01761968 2025-04-30
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
Italfarmaco
Phase 2 Active not recruiting